Literature DB >> 7666419

Solution structure of mithramycin dimers bound to partially overlapping sites on DNA.

M Sastry1, R Fiala, D J Patel.   

Abstract

Mithramycin (MTH) is a DNA-binding antitumor agent containing A-B disaccharide and C-D-E trisaccharide segments projecting from opposite ends of an aglycone chromophore. We have previously reported on the solution structure of the MTH-DNA 6-mer complex based on a combined NMR and molecular dynamics study. This study established that the Mg(2+)-coordinated mithramycin dimer bound to a widened minor groove centered about the sequence-specific (G-C).(G-C) site and that the C-D-E trisaccharide segments from individual monomers were directed towards opposite ends of the helix spanning a six base-pair segment. This research is now extended to the binding of mithramycin dimers to partially overlapping sites on the self-complementary d(T-A-G-C-T-A-G-C-T-A) 10-mer duplex. The six base-pair mithramycin dimer footprint centered about (G-C).(G-C) steps should result in a potential steric clash in the center of the helix involving the inwardly pointing E-sugars of the pair of mithramycin dimers bound to the DNA 10-mer duplex. The MTH-d(T-A-G-C-T-A-G-C-T-A) complex (two MTH dimers per duplex) yields narrow and well-resolved NMR spectra, which have been assigned to identify intramolecular and intermolecular nuclear Overhauser enhancement (NOE) connectivities in the complex. The solution structure of the MTH-DNA 10-mer complex based on distance-restrained molecular dynamics calculations has defined the conformation of the drug and the DNA necessary for accommodation of the pair of mithramycin dimers on the DNA 10-mer helix. Specifically, the inwardly pointing E-sugars retain their face-down alignment towards the floor of the minor groove and occupy adjacent binding sites in the center of the duplex. This is achieved, in part, through torsion angle differences in the glycosidic linkage bonds along the length of the inwardly pointing aglycone-C-D-E trisaccharide segment relative to its outwardly pointing aglycone-C-D-E trisaccharide counterpart in the complex. In addition, a pronounced kink at the central (T-A).(T-A) step opens the minor groove and generates additional space to accommodate the inwardly pointing E-sugars at adjacent sites in the MTH-DNA 10-mer complex. These studies establish conformational plasticity in the C-D-E trisaccharide segment of the mithramycin dimer and deformability of the DNA helix allowing mithramycin dimers to bind to partially overlapping minor groove sites on the DNA helix.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7666419     DOI: 10.1006/jmbi.1995.0464

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  27 in total

1.  Molecular insight into substrate recognition and catalysis of Baeyer-Villiger monooxygenase MtmOIV, the key frame-modifying enzyme in the biosynthesis of anticancer agent mithramycin.

Authors:  Mary A Bosserman; Theresa Downey; Nicholas Noinaj; Susan K Buchanan; Jürgen Rohr
Journal:  ACS Chem Biol       Date:  2013-09-13       Impact factor: 5.100

2.  Chromomycin SA analogs from a marine-derived Streptomyces sp.

Authors:  Youcai Hu; Ana Paula D M Espindola; Nathan A Stewart; Shuguang Wei; Bruce A Posner; John B MacMillan
Journal:  Bioorg Med Chem       Date:  2011-07-20       Impact factor: 3.641

3.  How mithramycin stereochemistry dictates its structure and DNA binding function.

Authors:  Caixia Hou; Jürgen Rohr; Sean Parkin; Oleg V Tsodikov
Journal:  Medchemcomm       Date:  2019-03-28       Impact factor: 3.597

4.  Cooperation of two bifunctional enzymes in the biosynthesis and attachment of deoxysugars of the antitumor antibiotic mithramycin.

Authors:  Guojun Wang; Pallab Pahari; Madan K Kharel; Jing Chen; Haining Zhu; Steven G Van Lanen; Jürgen Rohr
Journal:  Angew Chem Int Ed Engl       Date:  2012-09-20       Impact factor: 15.336

5.  Ketopremithramycins and ketomithramycins, four new aureolic acid-type compounds obtained upon inactivation of two genes involved in the biosynthesis of the deoxysugar moieties of the antitumor drug mithramycin by Streptomyces argillaceus, reveal novel insights into post-PKS tailoring steps of the mithramycin biosynthetic pathway.

Authors:  Lily L Remsing; Jose Garcia-Bernardo; Ana Gonzalez; Eva Künzel; Uwe Rix; Alfredo F Braña; Daniel W Bearden; Carmen Méndez; Jose A Salas; Jürgen Rohr
Journal:  J Am Chem Soc       Date:  2002-02-27       Impact factor: 15.419

6.  Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis.

Authors:  Lily L Remsing; Ana M González; Mohammad Nur-e-Alam; M José Fernández-Lozano; Alfredo F Braña; Uwe Rix; Marcos A Oliveira; Carmen Méndez; José A Salas; Jürgen Rohr
Journal:  J Am Chem Soc       Date:  2003-05-14       Impact factor: 15.419

7.  Crystal structure of the [Mg2+-(chromomycin A3)2]-d(TTGGCCAA)2 complex reveals GGCC binding specificity of the drug dimer chelated by a metal ion.

Authors:  Ming-Hon Hou; Howard Robinson; Yi-Gui Gao; Andrew H-J Wang
Journal:  Nucleic Acids Res       Date:  2004-04-23       Impact factor: 16.971

8.  Semi-synthetic mithramycin SA derivatives with improved anticancer activity.

Authors:  Daniel Scott; Jhong-Min Chen; Younsoo Bae; Jürgen Rohr
Journal:  Chem Biol Drug Des       Date:  2013-04-04       Impact factor: 2.817

9.  Mithramycin analogues generated by combinatorial biosynthesis show improved bioactivity.

Authors:  Irfan Baig; María Perez; Alfredo F Braña; Rohini Gomathinayagam; Chendil Damodaran; Jose A Salas; Carmen Méndez; Jürgen Rohr
Journal:  J Nat Prod       Date:  2008-01-15       Impact factor: 4.050

10.  Crystal structure of Baeyer-Villiger monooxygenase MtmOIV, the key enzyme of the mithramycin biosynthetic pathway .

Authors:  Miranda P Beam; Mary A Bosserman; Nicholas Noinaj; Marie Wehenkel; Jürgen Rohr
Journal:  Biochemistry       Date:  2009-06-02       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.